UroGen Pharma Ltd. Increase (Decrease) in Employee Related Liabilities
UroGen Pharma Ltd. (URGN) reported Increase (Decrease) in Employee Related Liabilities of -$1.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-08-05
- UroGen Pharma Ltd. increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was $2.42M, a 48.37% decline year-over-year.
- UroGen Pharma Ltd. increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was -$3.68M.
- UroGen Pharma Ltd. increase (decrease) in employee related liabilities for the quarter ending 2025-12-31 was $2.40M, a 55.87% increase year-over-year.
- UroGen Pharma Ltd. increase (decrease) in employee related liabilities for the quarter ending 2025-09-30 was -$532.00K, a 124.40% decline year-over-year.
- UroGen Pharma Ltd. increase (decrease) in employee related liabilities for fiscal 2025 was $2.95M.
- UroGen Pharma Ltd. increase (decrease) in employee related liabilities for fiscal 2024 was -$244.00K, a 109.54% decline from fiscal 2023.
- UroGen Pharma Ltd. increase (decrease) in employee related liabilities for fiscal 2023 was $2.56M, a 95.34% increase from fiscal 2022.
- UroGen Pharma Ltd. increase (decrease) in employee related liabilities for fiscal 2022 was $1.31M.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.26M 10-Q · filed 2026-08-05 | $1.14M derived: sum of 3 quarters · filed 2026-08-05 | $607.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$3.68M 10-Q · filed 2026-05-06 | -$1.28M derived: sum of 2 quarters · filed 2026-05-06 | -$1.81M derived: sum of 3 quarters · filed 2026-05-06 | $2.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.87M derived: sum of 2 quarters · filed 2026-03-02 | $6.55M derived: sum of 3 quarters · filed 2026-08-05 | $2.95M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$532.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.15M derived: sum of 2 quarters · filed 2026-08-05 | $544.00K 10-Q · filed 2025-11-06 | $2.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.08M 10-Q · filed 2026-08-05 | $2.62M derived: sum of 3 quarters · filed 2026-08-05 | $4.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$3.60M 10-Q · filed 2026-05-06 | -$2.06M derived: sum of 2 quarters · filed 2026-05-06 | $118.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.98M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.72M derived: sum of 2 quarters · filed 2026-03-02 | $5.58M derived: sum of 3 quarters · filed 2026-03-02 | -$244.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.04M derived: sum of 2 quarters · filed 2025-11-06 | -$1.78M 10-Q · filed 2025-11-06 | $877.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$3.96M 10-Q · filed 2025-08-07 | -$1.30M derived: sum of 3 quarters · filed 2025-08-07 | $128.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$5.83M 10-Q · filed 2025-05-12 | -$3.17M derived: sum of 2 quarters · filed 2025-05-12 | -$1.74M derived: sum of 3 quarters · filed 2025-05-12 | $66.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $4.09M derived: sum of 2 quarters · filed 2025-03-10 | $5.89M derived: sum of 3 quarters · filed 2025-03-10 | $2.56M 10-K · filed 2025-03-10 |
| 2023-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $3.23M derived: sum of 2 quarters · filed 2024-11-06 | -$105.00K 10-Q · filed 2024-11-06 | $1.53M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$1.54M 10-Q · filed 2024-08-13 | $96.00K derived: sum of 3 quarters · filed 2024-08-13 | $293.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$3.34M 10-Q · filed 2024-05-13 | -$1.71M derived: sum of 2 quarters · filed 2024-05-13 | -$1.51M derived: sum of 3 quarters · filed 2024-05-13 | -$228.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.83M derived: sum of 2 quarters · filed 2024-03-14 | $3.11M derived: sum of 3 quarters · filed 2024-03-14 | $1.31M 10-K · filed 2024-03-14 |
| 2022-09-30 | $197.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.48M derived: sum of 2 quarters · filed 2023-11-14 | -$323.00K 10-Q · filed 2023-11-14 | $149.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$520.00K 10-Q · filed 2023-08-10 | -$48.00K derived: sum of 3 quarters · filed 2023-08-10 | -$345.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$1.80M 10-Q · filed 2023-05-11 | -$1.33M derived: sum of 2 quarters · filed 2023-05-11 | -$1.63M derived: sum of 3 quarters · filed 2023-05-11 | $435.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $472.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $175.00K derived: sum of 2 quarters · filed 2023-03-24 | $2.24M derived: sum of 3 quarters · filed 2023-03-24 | -$2.61M 10-K · filed 2023-03-24 |
| 2021-09-30 | -$297.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.76M derived: sum of 2 quarters · filed 2022-11-10 | -$3.08M 10-Q · filed 2022-11-10 | -$1.31M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $2.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$2.78M 10-Q · filed 2022-08-11 | -$1.02M derived: sum of 3 quarters · filed 2022-08-11 | $1.03M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$4.84M 10-Q · filed 2022-05-10 | -$3.08M derived: sum of 2 quarters · filed 2022-05-10 | -$1.03M derived: sum of 3 quarters · filed 2022-05-10 | $637.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $3.81M derived: sum of 2 quarters · filed 2022-03-21 | $5.48M derived: sum of 3 quarters · filed 2022-03-21 | $2.84M 10-K · filed 2022-03-21 |
| 2020-09-30 | $2.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $3.72M derived: sum of 2 quarters · filed 2021-11-15 | $1.08M 10-Q · filed 2021-11-15 | $2.71M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$967.00K 10-Q · filed 2021-08-04 | $662.00K derived: sum of 3 quarters · filed 2021-08-04 | $2.04M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | -$2.64M 10-Q · filed 2021-05-13 | -$1.01M derived: sum of 2 quarters · filed 2021-05-13 | $369.00K derived: sum of 3 quarters · filed 2021-05-13 | $741.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $3.00M derived: sum of 2 quarters · filed 2021-03-18 | $3.38M derived: sum of 3 quarters · filed 2021-03-18 | $1.79M 10-K · filed 2021-03-18 |
| 2019-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $1.75M derived: sum of 2 quarters · filed 2020-11-09 | $157.00K 10-Q · filed 2020-11-09 | $2.40M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $372.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$1.22M 10-Q · filed 2020-08-10 | $1.02M derived: sum of 3 quarters · filed 2020-08-10 | $1.50M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | -$1.59M 10-Q · filed 2020-05-07 | $650.00K derived: sum of 2 quarters · filed 2020-05-07 | $1.12M derived: sum of 3 quarters · filed 2020-05-07 | $2.04M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $2.71M derived: sum of 2 quarters · filed 2020-03-02 | $3.63M derived: sum of 3 quarters · filed 2020-03-02 | $2.98M 10-K · filed 2020-03-02 |
| 2018-09-30 | $473.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $1.39M derived: sum of 2 quarters · filed 2019-11-12 | $734.00K 10-Q · filed 2019-11-12 | $1.54M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $920.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $261.00K 10-Q · filed 2019-08-09 | $1.07M derived: sum of 3 quarters · filed 2020-03-02 | $1.10M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$659.00K 10-Q · filed 2019-05-09 | $152.00K derived: sum of 2 quarters · filed 2020-03-02 | $179.00K derived: sum of 3 quarters · filed 2020-03-02 | $636.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $811.00K derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | $838.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.29M derived: sum of 3 quarters · filed 2020-03-02 | $1.26M 10-K · filed 2020-03-02 |
| 2017-09-30 | $27.00K derived: 6-K 9 month − 6-K 6 month · filed 2018-11-13 | $484.00K derived: sum of 2 quarters · filed 2018-11-13 | $452.00K 6-K · filed 2018-11-13 | |
| 2017-06-30 | $457.00K derived: 6-K 6 month − 6-K 3 month · filed 2018-08-14 | $425.00K 6-K · filed 2018-08-14 | ||
| 2017-03-31 | -$32.00K 6-K · filed 2018-05-15 | |||
| 2016-12-31 | $178.00K 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $191.00K 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |